AB0166 Tracking of mucocutanous and musculoskeletal flares in sle using serum fas, ferritin, igfbp2 and stnfrii. (12th June 2018)

• Record Type: Journal Article
• Authors: Soliman, S.; Vanarsa, K.; Swilling, A.; Merrill, J.; Mohan, C.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 1271
• Page End: 1271
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.1133
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: SLE is a multisystemic autoimmune disease characterized by unpredictable disease course with periods of flares and remission. The lack of reliable methods which can predict a disease flare hampers the exploration of effective and preventive strategies for disease relapses. Objectives: To study the performance of serum FAS, sTNFRII, Igfbp2 and Ferritin as biomarkers for tracking lupus flares in non-renal SLE patients. Methods: Twenty-nine patients, who met the requirements of American College of Rheumatology (ACR) for classification of SLE, were recruited from Oklahoma Medical Research Foundation (OMRF) for serological testing of all four serum protein markers. None of the patients had lupus nephritis. Serum samples were obtained over 4 consecutive visits. Serum FAS, sTNFRII, Igfbp2 and Ferritin molecules were measured in all patients. Lupus disease activity was assessed by both SLEDAI and BILAG activity indices. Results: In our study, all 4 tested biomarkers (FAS, Ferritin, Igfbp2 and sTNFRII) showed significant correlations with SLEDAI and BILAG. FAS (r= 0.36, p<0.0001 for SLEDAI & r= 0.29, p= 0.0002 for BILAG), Ferritin (r= 0.13, p=0.0494 for SLEDAI & r= 0.22, p= 0.0035 for BILAG), Igfbp2 (r= 0.24, p= 0.0013 for SLEDAI & r= 0.18, p= 0.0106 for BILAG) and sTNFRII (r= 0.30, p<0.0001 for SLEDAI & r= 0.19, p= 0.0112 for BILAG). When serial disease activity changes were examined, different serum markers performed better in different SLE patients, tracking with mucocutaneous or musculoskeletal disease flares. In studying a total of 72 disease intervals, FAS and Ferritin exhibited the highest concordance with concurrent disease activity (58–62%), followed by Igfbp2 (50%) and sTNFRII (46%), all of which were superior to the performance of complement C3, C4 and anti-DNA. Furthermore, adding FAS to other tested molecules increased its ability to track concordant disease activity changes (81% for FAS±Ferritin; 76% for FAS±Igfbp2 and FAS±sTNFRII). Conclusions: Serum FAS and Ferritin emerge as potential serum markers for tracking mucocutaneous or musculoskeletal disease flares in SLE patients. Disclosure of Interest: None declared